Patents by Inventor Richard A. Shimkets

Richard A. Shimkets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240400671
    Abstract: Disclosed are anti-IL-25 binding molecules and methods of using said binding molecules in the treatment of rhinoviral infection, coronavirus infection, airway inflammation, rheumatoid arthritis, asthma, osteoarthritis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disorder, allograft rejection, psoriasis, certain types of cancer, angiogenesis, atherosclerosis, cystic fibrosis and multiple sclerosis. Also disclosed are methods of using said binding molecules in the treatment of inflammation due to microbial infection, autoinflammatory disease, and/or autoimmune disease including, but not limited to rhinoviral infection, coronavirus infection, airway inflammation, rheumatoid arthritis, asthma, osteoarthritis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disorder, allograft rejection, psoriasis, certain types of cancer, angiogenesis, atherosclerosis, cystic fibrosis and multiple sclerosis.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 5, 2024
    Inventors: Richard A. SHIMKETS, Nathan BARTLETT, Crystal JACKSON
  • Publication number: 20240301048
    Abstract: Disclosed are compositions and methods related to anti-IL-17A antibodies and antigen binding fragments thereof. Additionally provided are bi-specific binding proteins comprising the anti-IL-17A binding domains. Additionally provided are methods of use for the compounds and compositions described herein in the treatment of inflammatory diseases and ocular disorders.
    Type: Application
    Filed: January 10, 2022
    Publication date: September 12, 2024
    Inventors: Daniel WHITE, Richard A. SHIMKETS, Crystal Lyles JACKSON, Thomas VINCENT, Yonghua LUO
  • Patent number: 11492397
    Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 8, 2022
    Assignee: ABEOME CORPORATION
    Inventors: Richard A. Shimkets, Crystal Lyles Jackson, Nathan Bartlett, Thomas Vincent, Yonghua Luo
  • Publication number: 20200291105
    Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.
    Type: Application
    Filed: March 9, 2017
    Publication date: September 17, 2020
    Inventors: Richard A. Shimkets, Crystal Lyles Jackson, Nathan Bartlett, Thomas Vincent, Yonghua Luo
  • Publication number: 20140186889
    Abstract: Certain transgenic animals which are prone to the rapid cell division of their antibody-secreting cells have superior properties for the generation of monoclonal antibodies. Not only can their antibody producing cells can be made into hybridomas with superior growth to hybridomas from non-prone animals, but the antibody producing cells themselves can be cultured directly without cell fusion or further manipulation. Disclosed herein are methods of making monoclonal antibodies comprising exposing the transgenic animals disclosed herein to an antigen and extracting antigen-specific antibody secreting cells from the transgenic animal.
    Type: Application
    Filed: April 16, 2012
    Publication date: July 3, 2014
    Applicant: Abeome Corporation
    Inventor: Richard A. Shimkets
  • Publication number: 20100158918
    Abstract: The invention provides polypeptides, designated herein as SECP polypeptides, as well as polynucleotides encoding SECP polypeptides, and antibodies that immunospecifically-bind to SECP polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the SECP polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 24, 2010
    Inventors: Richard A. Shimkets, Elma Fernandes
  • Patent number: 7291483
    Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-GX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: November 6, 2007
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, Sudhirdas K. Prayaga
  • Patent number: 7259144
    Abstract: The present invention describes novel methods for diagnosis and treatment of conditions that alter phosphate transport in mammals. The fibroblast growth factor proteins and nucleotides that may be useful as a therapeutic or in the diagnosis of such conditions are also described.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: August 21, 2007
    Assignee: CuraGen Corporation
    Inventor: Richard A. Shimkets
  • Patent number: 7253266
    Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: August 7, 2007
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, Michael Jeffers, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E. A. Pena, John P. Alsobrook, II, Denise M. Lepley, Daniel K. Rieger, William Grosse
  • Patent number: 7108972
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: September 19, 2006
    Assignee: CuraGen Corporation
    Inventors: Carol E. A. Pena, Richard A. Shimkets, Li Li, Suresh G. Shenoy, Ramesh Kekuda, Kimberly A. Spytek, Corine A. M. Vernet, Uriel M. Malyankar, Xiaojia (Sasha) Guo, Vladimir Y. Gusev, Stacie J. Casman, Ferenc L. Boldog, Katarzyna Furtak, Velizar T. Tchernev, Meera Patturajan, Esha A. Gangolli, Muralidhara Padigaru, Xiaohong Liu, Jason C. Baumgartner, Valerie Gerlach, Steven K. Spaderna, Bryan D. Zerhusen
  • Patent number: 7056885
    Abstract: The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.
    Type: Grant
    Filed: July 3, 2000
    Date of Patent: June 6, 2006
    Assignee: CuraGen Corporation
    Inventors: Michael Jeffers, Richard A. Shimkets, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein
  • Patent number: 7034132
    Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: April 25, 2006
    Inventors: David W. Anderson, Jason C. Baumgartner, Ferenc L. Boldog, Stacie J. Casman, Shlomit R. Edinger, Esha A. Gangolli, Valerie Gerlach, Linda Gorman, Xiaojia Guo, Tord Hjalt, Ramesh Kekuda, Li Li, John R. MacDougall, Uriel M. Malyankar, Isabelle Millet, Muralidhara Padigaru, Meera Patturajan, Carol E. A. Pena, Luca Rastelli, Richard A. Shimkets, David J. Stone, Kimberly A. Spytek, Corine A. M. Vernet, Edward Z. Voss, Bryan D. Zerhusen
  • Patent number: 7001766
    Abstract: This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to human angiopoietin-related proteins. The nucleic acid sequence is 1855 nucleotides long and contains an open reading frame from nucleotides 154-6 to 1369-71. The encoded polypeptides are about 405 amino acid residues in length.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 21, 2006
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, Elma Fernandes
  • Patent number: 6989232
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: January 24, 2006
    Assignees: Millennium Pharmaceuticals, Inc., Curagen Corporation
    Inventors: Catherine E. Burgess, Pamela B. Conley, William M. Grosse, Matthew Hart, Ramesh Kekuda, Richard A. Shimkets, Kimberly A. Spytek, Edward Szekeres, Jr., James E. Tomlinson, James N. Topper, Ruey-Bin Yang
  • Patent number: 6974684
    Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: December 13, 2005
    Assignee: CuraGen Corporation
    Inventors: David W. Anderson, John P. Alsobrook II, Ferenc L. Boldog, Catherine E. Burgess, Stacie J. Casman, Shlomit R. Edinger, Esha A. Gangolli, Linda Gorman, Xiaojia Sasha Guo, Nikolai Khramtsov, Denise M. Lepley, John R. MacDougall, Carol E. A. Pena, John A. Peyman, Meera Patturajan, Daniel K. Rieger, Richard A. Shimkets, Glennda Smithson, Kimberly A. Spytek, Corine A. M. Vernet, Edward Z. Voss, Mei Zhong
  • Patent number: 6942992
    Abstract: This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to slit-, MEGF- or multiple epidermal growth factor, and roundabout-proteins. The nucleic acid sequence is 2341 nucleotides long and contains an open reading frame from nucleotides 215 to 2173. The encoded polypeptides of 653 residues are novel.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: September 13, 2005
    Assignee: CuraGen Corporation
    Inventor: Richard A. Shimkets
  • Patent number: 6916907
    Abstract: Disclosed are osteoprotegerin-like polypeptides, nucleic acids encoding osteoprotegerin-like polypeptides, and methods of using these molecules. The osteoprotegerin-like polypeptides sequence homology to osteoprotegerin and tumor necrosis factor receptor molecules.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: July 12, 2005
    Assignee: CuraGen Corporation
    Inventors: Meijia Yang, Henri Lichenstein, William F. McDonald, Richard A. Shimkets
  • Patent number: 6875567
    Abstract: The present invention is based upon the identification of genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention provides nucleotide sequences of genes selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. The invention also provides therapeutic methods and pharmaceutical compositions which are based on the promotion or inhibition of the function of the differentially expressed genes. The invention further provides methods of diagnosis, prognosis and screening for a disposition for diseases or disorders associated with cardiac hypertrophy. Methods for screening for modulators of the protein products of the differentially expressed genes in cardiac hypertrophy tissue are additionally provided.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: April 5, 2005
    Assignees: Genentech, Inc., Curagen Corporation
    Inventors: Richard A. Shimkets, David G. Lowe
  • Patent number: 6875570
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: April 5, 2005
    Assignee: CuraGen Corporation
    Inventors: Valerie L. Gerlach, John R. MacDougall, Glennda Smithson, Isabelle Millet, David Stone, Erik Gunther, Karen Ellerman, William M. Grosse, John P. Alsobrook, II, Denise M. Lepley, Catherine E. Burgess, Muralidhara Padigaru, Ramesh Kekuda, Kimberly A. Spytek, Martin D. Leach, Richard A. Shimkets
  • Patent number: 6863889
    Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or selected polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provide methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: March 8, 2005
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, William J. LaRochelle